Modal Pain Management offers a physician-supervised medical weight loss program designed specifically for patients whose chronic pain is amplified by excess body weight. The program is run by Dr. Alex Movshis, a dual board-certified pain management physician and anesthesiologist, at our Midtown Manhattan practice (369 Lexington Avenue, Floor 25, NYC 10017). It is not a general weight-loss clinic and not a med-spa offering — it is a focused intervention for pain patients in whom weight is a measurable contributor to mechanical joint load, spine pain, or systemic inflammatory signaling.
Why Weight Matters in Pain Medicine
Two well-characterized mechanisms link excess weight to chronic pain:
Mechanical load on weight-bearing joints. During normal gait, the knee absorbs roughly four times body weight per step. Each pound of additional body weight translates to approximately four pounds of additional force on the knee joint and three pounds on the hip joint per step. Over years of repetition, this accelerates cartilage wear, drives osteoarthritic progression, and increases facet joint loading in the lumbar spine. Weight reduction directly reduces this mechanical input. Published meta-analyses of knee osteoarthritis (Messier et al., Arthritis & Rheumatism) demonstrate that approximately 5–10% body-weight loss produces clinically meaningful reductions in pain scores and improvements in WOMAC function scores in symptomatic patients.
Visceral adiposity and systemic inflammation. Adipose tissue — particularly visceral fat — is metabolically active and secretes pro-inflammatory cytokines including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and leptin. Elevated circulating inflammatory cytokines amplify peripheral and central pain signaling. This is one of the reasons obesity is associated with greater pain intensity in conditions like fibromyalgia, complex regional pain syndrome, chronic low back pain, and chronic migraine — beyond what mechanical loading alone explains.
For patients in whom weight is a contributing factor, addressing weight directly is part of the pain treatment plan, not a separate concern.
The GLP-1 Protocol
The current standard of care for pharmacologic weight reduction is the GLP-1 receptor agonist class — semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro). At Modal Pain Management, GLP-1 prescribing follows the published titration protocols and is integrated with the patient’s broader pain treatment plan.
Semaglutide titration (Wegovy protocol): weekly subcutaneous injection starting at 0.25 mg for the first four weeks, increasing to 0.5 mg, 1.0 mg, 1.7 mg, and reaching maintenance dosing of 2.4 mg by week 16–20. Slow titration is essential to manage GI side effects (nausea, early satiety, constipation, occasional vomiting).
Tirzepatide titration (Zepbound protocol): weekly subcutaneous injection starting at 2.5 mg for the first four weeks, increasing to 5 mg, then optionally to 7.5 mg, 10 mg, 12.5 mg, or 15 mg based on tolerability and response.
Realistic weight-loss expectation. STEP and SURMOUNT trial data: average total body weight loss with maximum-tolerated semaglutide is approximately 14.9% over 68 weeks; tirzepatide achieves approximately 20.9% at 15 mg over 72 weeks. Individual response varies. Patients who lose <5% of body weight by week 20 are typically reassessed for protocol adjustment or alternative approach.
Contraindications (absolute). Personal or family history of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2 (MEN 2). Known hypersensitivity to GLP-1 agonists. Use with caution in patients with a history of pancreatitis, severe gastroparesis, or active gallbladder disease. Pregnancy is a contraindication.
Common side effects. Nausea (most frequent, dose-related, usually attenuates within 4–8 weeks), constipation, diarrhea, early satiety, fatigue. Less common: cholelithiasis, acute pancreatitis, injection-site reactions. Patients are counseled in writing about every side-effect profile before the first dose.
Who This Program Is For
Modal Pain Management’s medical weight loss program is appropriate for:
- Patients with chronic knee, hip, or spine pain in whom imaging or examination shows weight-driven joint loading or facet joint pain.
- Patients with chronic widespread pain or fibromyalgia in whom inflammatory load is a likely amplifier.
- Patients managing chronic migraine who carry excess weight (obesity is an independent risk factor for chronic migraine progression).
- Patients recovering from interventional procedures (radiofrequency ablation, epidural steroid injections) who would otherwise re-load the same joints and re-trigger pain.
- Patients with metabolic syndrome or insulin resistance whose pain conditions are driven in part by inflammatory signaling.
This program is not appropriate for: cosmetic weight reduction without an associated pain indication, patients seeking GLP-1s without clinical follow-up, or patients with the absolute contraindications listed above.
What a Consultation Includes
The initial consultation runs 45–60 minutes. It includes:
- A focused pain history with attention to mechanical contributors and prior conservative care.
- Vital signs, BMI, waist-to-hip ratio, and a brief musculoskeletal examination.
- Medication review, focused on potential interactions with GLP-1 therapy (oral medications can be affected by delayed gastric emptying).
- Baseline laboratory work: comprehensive metabolic panel, hemoglobin A1c, lipid panel, TSH, lipase. Liver function and amylase are checked at follow-up if symptoms warrant.
- A written treatment plan with named protocol, titration schedule, follow-up cadence, and outcome targets.
Follow-Up Cadence
GLP-1 patients are seen every 4–8 weeks during titration and quarterly during maintenance. Each visit includes weight, blood pressure, side-effect review, and reassessment of the pain indication that drove the prescription. Patients who achieve their pain-and-weight goals typically transition to a maintenance dose or, in select cases, taper while continuing pain treatment.
Insurance and Cost
GLP-1 weight loss medications are inconsistently covered by commercial insurance plans. Coverage often requires documentation of an obesity diagnosis (BMI ≥30 or ≥27 with comorbidity) and may require prior authorization. Modal Pain Management’s billing team verifies coverage in advance and provides written cost projection before the first prescription. Modal Pain Management does not currently accept Medicare or Medicaid; patients with those plans should consult their plan directory for in-network providers.
For self-pay patients, current GLP-1 wholesale and compounded options are discussed transparently at consultation. See the insurance and billing page for the full verification process.
What This Program Is Not
Modal Pain Management does not offer:
- Standalone “wellness” or aesthetic weight-loss services without a pain indication.
- Mobile or unsupervised GLP-1 dispensing.
- HCG injections, “lipotropic” cocktails marketed as fat-burning, or unregulated peptide therapies.
- Weight-loss treatment without baseline laboratory work and physician follow-up.
The program operates within the discipline and oversight standards of pain medicine and anesthesiology — the specialties Dr. Movshis is board-certified in. See the credentials & verification page for the full training and certification record.
